Trial Profile
A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) Following a Two-Week Washout Period
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric citrate (Primary)
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Keryx Biopharmaceuticals
- 19 Dec 2014 New trial record